3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
53
Neoplasm Metastasis
6
Endometrial Neoplasms
5
Polycystic Ovary Syndrome
4
Ovarian Neoplasms
4
Neoplasms
4
Advanced Breast Cancer
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Neoplasms by Site
2
Infertility
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sexual Dysfunctions, Psychological
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Interventions
ribociclib
1
palbociclib
1
exemestane
1
abemaciclib
1
Letrozole
1
Fulvestrant
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unilateral Breast Neoplasms
×
Letrozole
×
90 days
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled